Study: Cartiva SCI an effective for toe osteoarthritis treatment — 4 points

Anuja Vaidya -   Print  |

Cartiva announced that the results of a study comparing the efficacy and safety of the Cartiva Synthetic Cartilage Implant to arthrodesis for treatment of advanced-stage hallux rigidus.

Here are four points:


1.  The results of the MOTION Study, a 236-patient prospective, randomized multi-center study, were published as a paper in Foot and Ankle International.


2. The paper concluded Cartiva SCI was "an excellent alternative to arthrodesis in patients who wished to maintain first MTP motion."


3. The paper was awarded the Roger A. Mann Award at the 2015 Annual Meeting of the American Orthopaedic Foot and Ankle Society. The award is given in recognition of the outstanding clinical paper presented at the meeting.


4. On April 20, the FDA's Orthopaedic and Rehabilitation Devices Panel voted in favor of Cartiva SCI with respect to safety, efficacy and risk/benefit ratio.


More articles on devices:
Blue Belt Technologies co-founder wins outstanding entrepreneur award: 5 things to know
Novastep, Vivex Biomedical partner: 4 points
45 spine, orthopedic devices receive FDA 510(k) clearance in April

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers